Overview Research Programs Shared Facilities News & Outreach Technology Transfer Employment About PHRI


March 14, 2018: Students, faculty and staff in solidarity with Florida shooting victims and all who have suffered from gun violence


Faculty Positions in Infectious Disease Research

The Public Health Research Institute (PHRI; www.phri.org) of New Jersey Medical School, Rutgers Biomedical and Health Sciences, located in Newark, New Jersey, is recruiting two faculty members at the intermediate or senior levels. PHRI is a leading infectious disease research center that emphasizes basic and translational sciences. Candidates must have a Ph.D. and/or an M.D. and a funded research program addressing critical questions in fungal, bacterial, or viral biology and/or host responses. Concurrent active clinical practice will also be highly regarded. Preference will be given to programs focused on respiratory infections. PHRI is housed in a state of the art research facility that has extensive core services, including a nationally designated BSL3 laboratory and animal facilities and an X-ray facility for structural studies. PHRI offers a robust and highly collegial research environment, generous start-up funds, and a comprehensive benefits package. Candidates should submit a curriculum vitae, a statement of research interests and accomplishments, and a list of at least three references.

Any questions or applications should be sent to: Dr. Barry Kreiswirth, Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, 225 Warren Street, Newark, NJ 07103. Telephone: (973) 854-3240. Fax: (973) 854-3101. Email: kreiswba@njms.rutgers.edu

Rutgers, the State University of New Jersey, is an Equal Opportunity/Affirmative Action employer, and is compliant with the Americans with Disabilities Act (ADA). For more information, please visit www.recruitment.rutgers.edu. Women and minorities are encouraged to apply.

To download a PDF copy of the recruitment advertisement, select PDF Document.

  04.04.18   www.yahoo.com: Drug-Resistant 'Nightmare Bacteria' Pose Growing Threat: CDC
  04.04.18   www.yahoo.com: Deadly ‘Nightmare Bacteria’ Resistant to Antibiotics Infected 221 Americans in a Year, CDC Says
  02.01.18   www.life-worldwide.org: February 1: World Aspergillosis Day
  12.01.17   www.asbmb.org: In memoriam: Harvey Penefsky
  11.13.17   www.who.int: World Antibiotic Awareness Week, 13-19 November 2017

  05.22.18   David Perlin's group and Cidara Therapeutics were awarded a $5.5 million NIH grant to support the development of novel immunotherapy agents targeting multi-drug resistant Gram-negative bacterial infections. Visit www.businesswire.com to read the press release.
  03.13.18   Drs. Liang Chen and Barry Kreiswirth participated in a study that shows the potential of an antibody approach to treat multidrug-resistant Klebsiella pneumoniae. Visit www.niaid.nih.gov to read the NIH press release and follow this link to download a PDF copy of the publication describing their work.
  03.06.18   Drs. Marras, Kramer, Tyagi and Vargas-Gold were awarded US Patent 9,909,159 for their invention of a novel PCR method, utilizing so-called "SuperSelective Primers", which is highly specific and sensitive and allows the detection and identification of rare mutant sequences in a background of abundant wild-type sequences, even if the difference between the sequences is a single nucleotide polymorphism.
  01.30.18   A Postdoctoral position is available in the laboratory of Dr. Selvakumar Subbian. Visit Employment Opportunities for details.
  01.26.18   Dr. David Perlin, executive director of PHRI, was among a select group of fellows elected into the American Academy of Microbiology. For details, please visit: www.asm.org.


Follow us on:    
     Copyright © 2018 All rights reserved.   PHRI at ICPH 225 Warren St. Newark, NJ 07103-3535 TEL 973 854 3100, FAX 973 854 3101